Bleeding because of impaired platelet function is a major side effect of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback